CiPA initiative and validation of high-throughput methods to characterize compound effects in human iPSC-derived cardiomyocytes

Use iPSC-derived cardiomyocytes for evaluation of compound effects and potential cardiotoxicity

Muthukrishnan Renganathan, PhD, Senior Scientist I Eurofins Discovery
Panida Lertkiatmongkol, PhD, Senior Scientist-Group Leader, Cell-based Screening I Eurofins Discovery
Oksana Sirenko, PhD, Senior Research Scientist I Molecular Devices
Carole Crittenden, Applications Scientist I Molecular Devices

View the webinar to:

• Hear the latest news on the CiPA initiative
• Learn how to evaluate compound induced effects on hiPSC-derived cardiomyocytes
• See the new features of the FLIPR Penta system and ScreenWorks® Peak Pro 2 software